Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Beta rhythm

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    52 result(s) found for: Beta rhythm. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2015-002168-17 Sponsor Protocol Number: BAY94-8862/16275 Start Date*: 2015-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in...
    Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    20.0 100000004849 10066498 Cardiac failure chronic aggravated LLT
    21.0 100000004857 10076408 Chronic kidney disease stage 1 LLT
    21.0 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002239-11 Sponsor Protocol Number: MYK-491-003 Start Date*: 2019-04-18
    Sponsor Name:MyoKardia Inc.
    Full Title: Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses...
    Medical condition: Heart Failure with Reduced Ejection Fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014940-12 Sponsor Protocol Number: CL2-44121-006 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhyt...
    Medical condition: Chronic Heart Failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007558 Cardiac failure chronic LLT
    12.1 10049694 Left ventricular dysfunction LLT
    12.1 10047281 Ventricular arrhythmia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) SK (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004450-21 Sponsor Protocol Number: EMR200136-570 Start Date*: 2014-02-07
    Sponsor Name:Merck Serono S.p.A.
    Full Title: Multicenter, open-label, 12 weeks, phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a (Rebif®) administered In the morning may affEct the severity of Flu-like syndrom...
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005302-26 Sponsor Protocol Number: DW.0701.005.2020P Start Date*: 2023-01-05
    Sponsor Name:John Paul II Hospital
    Full Title: The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction
    Medical condition: heart failure with moderately reduced ejection fraction (HFmrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005989-34 Sponsor Protocol Number: 034B20 Start Date*: 2022-08-31
    Sponsor Name:Aphaia Pharma AG
    Full Title: A Phase II, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese s...
    Medical condition: Obesity with/without associated endocrine and/or metabolic conditions and/or hypertension and/or NASH and/or NAFL with/without fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000641-13 Sponsor Protocol Number: BIO89-100-221 Start Date*: 2020-09-30
    Sponsor Name:89bio, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia
    Medical condition: Severe Hypertriglyceridemia (SHTG)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005048-17 Sponsor Protocol Number: VRP080415 Start Date*: 2009-01-27
    Sponsor Name:Verona Pharma Plc
    Full Title: A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics
    Medical condition: Allergic Asthma and Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002429-39 Sponsor Protocol Number: Leodor2017 Start Date*: 2017-10-27
    Sponsor Name:Medical University Innsbruck
    Full Title: REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILURE
    Medical condition: Advanced chronic heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) HU (Completed) SI (Completed) FI (Completed) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002681-39 Sponsor Protocol Number: PHI113747 Start Date*: 2013-12-20
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A 24-week, Phase 2B, randomized, active-controlled, parallel group, multi-center study to evaluate the safety and efficacy of GSK1278863 in subjects with anemia associated with chronic kidney disea...
    Medical condition: Anemia associated with chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) GB (Completed) CZ (Completed) HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004825-14 Sponsor Protocol Number: D1680C00016 Start Date*: 2016-05-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin, Saxagliptin Combined with Dapagliflozin, and Sitagliptin in Pat...
    Medical condition: Patients with type 2 diabetes mellitus and heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-016378-34 Sponsor Protocol Number: MI-CP204 Start Date*: 2010-06-30
    Sponsor Name:MedImmune LLC
    Full Title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
    Medical condition: Relapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL)...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 15:46:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA